PBAC's latest decision on Apomorphine hydrochloride: Recommended with restriction (2018). Considered for Treatment of Parkinson's disease in patients with severely disabling motor fluctuations which have not responded to other therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2014
Submissions
2
2014 → 2018
Eligible population
Patients with Parkinson's disease who have experienced severely disabling motor fluctuations which have not responded to other therapy.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
apomorphine hydrochloride 20 mg/2 mL ampoule
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission assumed cost neutrality based on equivalent cost per mg as existing apomorphine forms.
Submission history
Nov 2014: Recommended with restriction · Authority Required
Mar 2018: Recommended with restriction · Authority Required